Top

Published in:

09-08-2023 | Kidney Cancer | RESEARCH ARTICLE

Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study

Authors: Jesús García-Donas, Guillermo de Velasco, Rodrigo Madurga, Jesús Chamorro, Diana Rosero, Olatz Etxaniz, Jose Luis Pérez-Gracia, Álvaro Pinto, Diego Cacho, María Barba, Pablo Borrega, Martín Lázaro, Laura Rodriguez, Laura Villalobos, Lourdes García, Andrés Cuellar, María Pilar Solís-Hernández, Amalia González, Cristina Pernaut, Juan Francisco Rodríguez-Moreno

Published in: Clinical and Translational Oncology | Issue 3/2024

Abstract

Background

Cancer is a risk factor for developing severe COVID19. Additionally, SARS-CoV2 has a special tropism for renal cells and complications like thrombosis or cytokine storm could be enhanced by standard treatments in kidney cancer (i.e., antiangiogenics or immunotherapy). Thus, understanding the impact of COVID19 in patients with this tumor is key for their correct management.

Methods

We designed a retrospective case–control study comparing the outcome of three groups of advanced kidney cancer patients on systemic treatment: cohort A (developed COVID19 while on antiangiogenics), cohort B (developed COVID19 while on immunotherapy) and cohort C (non-infected). Matching factors were age, gender, and treatment.

Results

95 patients were recruited in 16 centers in Spain from September 2020 to May 2021. Finally, 85 were deemed as eligible (23 cohort A, 21 cohort B, 41 cohort C).

Patients with COVID required more dose interruptions (25 vs. six) and hospitalizations (10 vs. none) than those without COVID (both p = 0.001). No difference between cohorts A and B was observed regarding hospitalization or length of stay. No ICU admission was registered and one patient in cohort B died due to COVID19. Regarding cancer evolution, three patients in cohort A presented progressive disease after COVID19 compared to two in cohort B. One case in cohort B, initially deemed as stable disease, achieved a partial response after COVID19.

Conclusions

Kidney cancer patients who developed COVID19 while on systemic therapy required more treatment interruptions and hospitalizations than those non-infected. However, no significant impact on cancer outcome was observed. Also, no difference was seen between cases on antiangiogenics or immunotherapy.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3.CrossRefPubMedPubMedCentral

Zhang H, Han H, He T, Labbe KE, Hernandez AV, Chen H, et al. Clinical characteristics and outcomes of COVID-19-infected cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2021;113(4):371–80. https://doi.org/10.1093/jnci/djaa168.CrossRefPubMed

Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052–9. https://doi.org/10.1001/jama.2020.6775.CrossRefPubMedPubMedCentral

Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382(17):1653–9. https://doi.org/10.1056/NEJMsr2005760.CrossRefPubMed

Ahmadian E, Hosseiniyan Khatibi SM, Razi Soofiyani S, Abediazar S, Shoja MM, Ardalan M, et al. Covid-19 and kidney injury: pathophysiology and molecular mechanisms. Rev Med Virol. 2021;31(3):e2176. https://doi.org/10.1002/rmv.2176.CrossRefPubMed

Choong OK, Jakobsson R, Bergdahl AG, Brunet S, Kärmander A, Waldenström J, et al. SARS-CoV-2 replicates and displays oncolytic properties in clear cell and papillary renal cell carcinoma. PLoS ONE. 2023;18(1):e0279578. https://doi.org/10.1371/journal.pone.0279578.CrossRefPubMedPubMedCentral

Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089–98. https://doi.org/10.1007/s00134-020-06062-x.CrossRefPubMedPubMedCentral

Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473–4. https://doi.org/10.1126/science.abb8925.CrossRefPubMedADS

Labaki C, Peters S, Choueiri TK. Treatment decisions for patients with cancer during the COVID-19 pandemic. Cancer Discov. 2021;11(6):1330–5. https://doi.org/10.1158/2159-8290.CD-21-0210.CrossRefPubMed

10.

Rubinstein SM, Steinharter JA, Warner J, Rini BI, Peters S, Choueiri TK. The COVID-19 and Cancer Consortium: a collaborative effort to understand the effects of COVID-19 on patients with cancer. Cancer Cell. 2020;37(6):738–41. https://doi.org/10.1016/j.ccell.2020.04.018.CrossRefPubMedPubMedCentral

11.

Ürün Y, Hussain SA, Bakouny Z, Castellano D, Kılıçkap S, Morgan G, et al. Survey of the impact of COVID-19 on oncologists’ decision making in cancer. JCO Glob Oncol. 2020;6:1248–57. https://doi.org/10.1200/GO.20.00300.CrossRefPubMed

12.

Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–9. https://doi.org/10.1200/JCO.2008.21.4809.CrossRefPubMed

13.

Grivas P, Khaki AR, Wise-Draper TM, French B, Hennessy C, Hsu CY, et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol. 2021;32(6):787–800. https://doi.org/10.1016/j.annonc.2021.02.024.CrossRefPubMed

14.

Challenor S, Tucker D. SARS-CoV-2-induced remission of Hodgkin lymphoma. Br J Haematol. 2021;192(3):415. https://doi.org/10.1111/bjh.17116.CrossRefPubMed

15.

Sollini M, Gelardi F, Carlo-Stella C, Chiti A. Complete remission of follicular lymphoma after SARS-CoV-2 infection: from the “flare phenomenon” to the “abscopal effect. J Nucl Med Mol Imaging. 2021;48:2652–4. https://doi.org/10.1007/s00259-021-05275-6.CrossRef

16.

Aeppli S, Eboulet EI, Eisen T, Escudier B, Fischer S, Larkin J, et al. Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. ESMO Open. 2020;5:e000852.CrossRefPubMedPubMedCentral

17.

Luo J, Rizvi H, Egger JV, Preeshagul IR, Wolchok JD, Hellmann MD. Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers. Cancer Discov. 2020;10(8):1121–8. https://doi.org/10.1158/2159-8290.CD-20-0596.CrossRefPubMedPubMedCentral

18.

Rogiers A, Pires da Silva I, Tentori C, Tondini CA, Grimes JM, Trager MH, et al. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. J Immunother Cancer. 2021;9(1):e001931.CrossRefPubMed

Title: Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study
Authors: Jesús García-Donas
Guillermo de Velasco
Rodrigo Madurga
Jesús Chamorro
Diana Rosero
Olatz Etxaniz
Jose Luis Pérez-Gracia
Álvaro Pinto
Diego Cacho
María Barba
Pablo Borrega
Martín Lázaro
Laura Rodriguez
Laura Villalobos
Lourdes García
Andrés Cuellar
María Pilar Solís-Hernández
Amalia González
Cristina Pernaut
Juan Francisco Rodríguez-Moreno
Publication date: 09-08-2023
Publisher: Springer International Publishing
Keywords: Kidney Cancer
Kidney Cancer
Kidney Cancer
Published in: Clinical and Translational Oncology / Issue 3/2024
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-023-03295-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2024

Capecitabine/cisplatin combined with concurrent intensity-modulated radiation therapy: a feasible therapeutic strategy for anal squamous cell carcinoma

LncRNA XXYLT1-AS2 promotes tumor progression via autophagy inhibition through ubiquitinated degradation of TFEB in hepatocellular carcinoma

Difficulties on the access to innovative targeted therapies for lung cancer in Spain

The relationship between brain metastasis and HER2 expression status in gastric cancer

MMP11 and MMP17 are potential biomarkers for uterine corpus endometrial carcinoma prognosis

Outcomes with atezolizumab in metastatic urothelial cancer: real-world data from a single institution

Keynote webinar | Spotlight on antibody–drug conjugates in cancer